Awaiting a billion-dollar deal
Another cancer tech player that McDonald holds is Immutep Ltd (ASX: IMM).
Its share price has halved since November, giving it a current market capitalisation of around $310 million.
With the company targeting a US$50 billion addressable market in breast, lung, head & neck cancer markets, McDonald is convinced Immutep is undervalued.
“Similar biotech deals, either licensing or takeover, would probably be in the US$2 to US$5 billion range. So very substantial upside.”
Immutep has been granted a “prestigious” oral presentation at the American Society of Clinical Oncology conference on 3 June.
“It’s the largest healthcare conference in the world,” said McDonald.
“We can only assume it’s very good news… We’re greatly looking forward to that.”
- Forums
- ASX - By Stock
- IMM
- Ann: New & significant data from AIPAC phase 2b trial in MBC
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-38
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
34.0¢ | 35.5¢ | 34.0¢ | $738.6K | 2.115M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 260923 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.5¢ | 72865 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 106424 | 0.350 |
14 | 95566 | 0.345 |
8 | 45314 | 0.340 |
9 | 94317 | 0.335 |
8 | 126025 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.355 | 386705 | 38 |
0.360 | 367887 | 13 |
0.365 | 186494 | 10 |
0.370 | 307445 | 9 |
0.375 | 112765 | 6 |
Last trade - 13.15pm 16/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |